Related Experiment Video
Updated: Oct 27, 2025
A Novel Inhalation Mask System to Deliver High Concentrations of Nitric Oxide Gas in Spontaneously Breathing Subjects
Published on: May 4, 2021
Use of Inhaled Nitric Oxide in Preterm Infants: Is There Sufficient Evidence?
Amelie Stritzke1,2,3, Vineet Bhandari4, Abhay Lodha5,6,7,8
1Department of Pediatrics, Foothills Medical Centre, 780-1403 29th St NW, Calgary, AB T2N 2T9, Canada. amelie.stritzke@albertahealthservices.ca.
Abstract:
Nitric oxide (NO) is a potent vasodilator. The inhaled form (iNO) improves outcomes in term infants with persistent pulmonary hypertension of the newborn (PPHN) or bronchopulmonary dysplasia-associated pulmonary hypertension in preterm infants. However, in preterm infants, the risks and benefits of iNO use are controversial. Substantial evidence reveals no significant impact on survival or other morbidities in preterm infants with iNO treatment, independent of indication, timing, or duration of use. Many scientific organizations do not recommend the use of iNO in preterm infants, except in unique clinical circumstances with echocardiographic findings of PPHN in the setting of presumed pulmonary hypoplasia.
Related Concept Videos
01:19Respiratory Assessment: Purpose and Indications
Objectives and Importance:
The primary goal of respiratory assessment is to evaluate patients at early risk of clinical deterioration. Since respiratory distress often precedes other signs of declining health, breathing patterns and sounds become a...
01:28Nitric Oxide Signaling Pathway